[针对炎症性,自身免疫性和瘤性皮肤疾病的单克隆抗体]
Maria Kinberger1,2, Gabor Dobos3,4, Farzan Solimani3,5
1Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Deutschland. maria.kinberger@charite.de.
针对特定细胞抗原的单克隆抗体 (mAbs) 已经彻底改变了各种疾病的治疗方法. 本综述涵盖了针对炎症性和瘤性皮肤疾病的已批准和新兴的mAbs,提供了更好的结果和安全性.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 皮肤病学 皮肤病学
背景情况:
- 针对CD20的单克隆抗体 (mAbs) 与rituximab一样,于1997年首次被批准用于非霍奇金淋巴瘤.
- 了解疾病免疫病原发生的进步推动了针对各种抗原的mAbs的开发.
- 现在mAbs是治疗炎症性皮肤疾病和某些癌症的组成部分.
研究的目的:
- 审查目前批准的和新兴的单克隆抗体皮肤病的现状.
- 通过mAbs.突出治疗炎症和瘤性皮肤疾病的治疗进展.
- 为了比较mAbs与传统治疗的疗效和安全性.
主要方法:
- 对已批准用于皮肤疾病的单克隆抗体进行文献审查.
- 对有效性和安全性概况的临床数据的分析.
- 目前正在进行的研究和有前途的新 mAb 目标的总结.
主要成果:
- mAbs已被批准用于治疗成人和儿科患者的牛皮,亚托邦性皮肤炎和性腺炎.
- 与类固醇和其他免疫抑制剂相比,这些疗法显示出良好的结果和安全性.
- mAbs是针对恶性黑色素瘤和默克尔细胞癌等皮肤癌的成熟治疗方法.
结论:
- 单克隆抗体疗法代表了皮肤病学和瘤学的重大进展.
- mAbs为各种皮肤疾病提供有针对性和有效的治疗选择.
- 未来的研究将继续扩大mAbs在治疗复杂皮肤疾病中的作用.
更多相关视频
07:36Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
11:10Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
Published on: June 29, 2016
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
